TB-7251 · REV A · Technical newsheet

Lab InstrumentationDevice profile

Merck KGaA to Buy Rapid Micro Biosystems at $0.75 Per Share

Merck KGaA will pay $0.75 per share in cash for Rapid Micro Biosystems, folding the Growth Direct automated microbial QC platform into its Life Science business by December 2026.

By Sophie Lindqvist3 min read503 words

Features

  • Merck KGaA to acquire Rapid Micro Biosystems (Nasdaq: RPID) at $0.75 per share, all cash.
  • Deal structured as a tender offer; expected close December 2026.
  • Target's Growth Direct platform automates microbial QC testing for biologics, vaccines, cell and gene therapies, and sterile injectables.
  • Companies built an 18-month partnership before the acquisition, per CEO Robert Spignesi.
  • Rapid Micro Biosystems operates from Lexington and Lowell, Massachusetts, plus sites in Switzerland, Germany and the Netherlands.
Merck KGaA to Acquire Rapid Micro Biosystems for $0.75 Per Share in Cash
Device photoMerck KGaA to Acquire Rapid Micro Biosystems for $0.75 Per Share in Cash — AI-generated

Merck KGaA, Darmstadt, Germany, will pay $0.75 per share in cash for Rapid Micro Biosystems (Nasdaq: RPID), the Massachusetts developer of the Growth Direct automated microbial QC platform. The deal, structured as a tender offer for all outstanding shares, is expected to close in December 2026, subject to the minimum tender condition and customary closing requirements. The companies did not disclose the aggregate equity value.

For practitioners in sterile manufacturing, the target matters more than the price. Growth Direct automates microbial quality-control testing for makers of biologics, vaccines, cell and gene therapies, and sterile injectables — product classes where traditional compendial methods (culture-based incubation read by eye) impose days of lag before release decisions.

What does the platform actually replace?

Rapid Micro Biosystems positions Growth Direct against manual testing workflows in pharmaceutical QC labs. The company claims its automated systems deliver faster results, improve data integrity, and support regulatory compliance during manufacturing. Note the framing: these are vendor positioning statements about workflow outcomes, not independent head-to-head performance figures against pharmacopoeial reference methods, and the announcement gives no specific time-to-result or assay validation data.

That said, the buyer has been kicking the tires. "Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping customers modernize and automate their quality-control workflows," said Robert Spignesi, president and chief executive officer of Rapid Micro Biosystems. An 18-month partnership preceding the acquisition reads like an extended technical evaluation, not an impulse purchase.

Where does Growth Direct land?

Post-close, Rapid Micro Biosystems becomes part of Merck KGaA's Life Science business, expanding that unit's portfolio of automation technologies for pharmaceutical manufacturing and QC. Spignesi said the acquisition would extend the Growth Direct platform's reach through Merck KGaA's global life sciences operations and customer relationships — a distribution question that matters for labs outside the largest pharma hubs.

Paolo Carli, head of Advanced Solutions for Merck KGaA's Life Science business, framed the purchase around customer demand: "Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance."

Rapid Micro Biosystems counts many of the world's largest pharmaceutical manufacturers among its customers, according to the company. Headquartered in Lexington, Massachusetts, it runs a U.S. manufacturing facility in Lowell, Massachusetts, and maintains international locations in Switzerland, Germany, and the Netherlands.

Who is advising, and what's left to clear?

Perella Weinberg Partners serves as financial advisor to Rapid Micro Biosystems, with Goodwin Procter LLP providing legal counsel. The proposed acquisition remains subject to completion of the tender offer and applicable closing conditions — no regulatory approvals beyond customary requirements were itemized in the announcement.

The open question for QC lab managers: whether Merck's ownership accelerates or slows the platform's method-approval trajectory across pharmacopoeias and individual product filings. Buyers of rapid-microbial-method instrumentation ultimately commit to a validation pathway, not just a box.

via citybiz.co (Source)

Filed under

  • rapid-micro-biosystems
  • growth-direct
  • rapid-microbial-testing
  • pharmaceutical-quality-control
  • lab-automation
Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

News editor covering regulation, policy and their impact on Instruments, test and measurement at Testbench Report.

110 articles

Application notes

« Previous articleNext article »